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The anaplastic lymphoma kinase (ALK) is a transmembrane tyrosine kinase encoded onchromosome 2.1 It was first described as one of the fusion partners within a reciprocal
translocation (t(2;5)(p23;q35)) occurring in anaplastic large cell lymphoma.2,3 Activation
of ALK through chromosomal rearrangements (inversions or translocations) that fuse
various 5 partners with the 3 kinase domain of ALK have since been described in several
other malignancies, including non-small cell lung cancer.1,4 In lung cancer, the most
common 5 fusion partner for ALK is EML4, but two other fusion partners, KIF5B and
TFG, have also been reported.5–7
Interest in this chromosomal arrangement in lung cancer has been piqued by clinical
trials of crizotinib (PF-02341066), a dual MET/ALK inhibitor that has shown astonishing
clinical activity in patients with ALK rearrangements proven by fluorescence in situ
hybridization (FISH) using the Vysis ALK break-apart probe set.8 Registration studies
comparing crizotinib to standard chemotherapy in this population are ongoing, and Pfizer
has also announced plans to file with the Food and Drug Administration for accelerated
approval based on the initial phase I results.
A major limitation, both in implementing these ongoing trials and in getting access
to the drug, if it were to be licensed for a molecularly defined indication, is the small
proportion of lung cancer patients who have ALK rearrangements. A recent meta-analysis
has indicated that only 4% of lung cancers have ALK rearrangements.4 How to best
identify this 4% and which ALK testing method should be employed are rapidly becoming
crucial issues in the optimal management of patients with lung cancer.
FISH is the current gold standard used as an entry criterion for all the crizotinib
trials to date. The break-apart format of the FISH probe allows detection of rearrange-
ments involving the tyrosine kinase domain of ALK independent of the fusion partner or
specific breakpoint. The cut point for determination of a positive result has been set for the
lung cancer trials at more than 15% of tumor cells positive for split red and green signals
(separated by more than two signal diameters) or single red (3) signals.8,9 Yet, FISH
requires specialized laboratory techniques, expert interpretation, and may also be viewed
as a relatively expensive screening assay.
A potential alternative to FISH screening is immunohistochemistry (IHC). The ALK
protein is expressed at very low levels in most normal tissues, and its presence in a tumor
specimen could be sufficiently abnormal as to indicate an oncogenic role in those cells.1
Unlike techniques such as reverse transcriptase polymerase chain reaction, which are
fusion partner specific, IHC, similar to the break-apart FISH assay, should detect ALK
independent of the fusion partner within any rearrangement. However, as the 5 fusion
partner also contains the promoter for the fusion gene, absolute levels of protein (and the
cellular location of the signal) could still vary depending on the 5 partner. Two studies
*Division of Medical Oncology and †Department of Pathology, University of Colorado Comprehensive Cancer Center, Aurora, Colorado.
Disclosure: D. Ross Camidge, MD, PhD, serves on the advisory board for Pfizer and has received research funding from Pfizer, Lilly, and Novartis. Fred R.
Hirsch, MD, PhD, serves on the advisory board for Pfizer, has received research funding from Ventana and Roche, and holds a patent for EGFR FISH.
Marileila Varella-Garcia, PhD, holds a patent for EGFR FISH. Wilbur A. Franklin, MD, holds a patent for EGFR FISH.
Author for correspondence: D. Ross Camidge, MD, PhD, Room ACP 2256, Anschutz Cancer Pavillion, University of Colorado, Aurora, CO 80045. E-mail:
ross.camidge@ucdenver.edu
Copyright © 2011 by the International Association for the Study of Lung Cancer
ISSN: 1556-0864/11/0603-0411
Journal of Thoracic Oncology • Volume 6, Number 3, March 2011 411
in this issue of Journal of Thoracic Oncology address the role
of IHC in ALK screening lung cancer.10,11 One whole section
study performed in the United States and the other a tissue
microarray study performed in South Korea compared the
results of immunohistochemical staining for ALK with FISH
testing. Table 1 summarizes the major points of the two
studies. Each group used the intensity and frequency of
staining to assign arbitrary scores (0 to 3) to each specimen.
All FISH-positive cases exhibited some level of ALK stain-
ing, while all IHC-negative cases were also negative for ALK
rearrangements by FISH (100% sensitivity). However, spec-
ificity was not as robust. While highly positive IHC cases
(3) were uniformly FISH positive, many cases with lower
levels of immunostaining were FISH negative. Each group of
investigators conducted their study in slightly different ways.
We know, for example, that certain lung cancer subgroups are
more likely to have an ALK rearrangement than others. In our
recent Colorado series, FISH testing among patients with
adenocarcinoma, 10 pack-year smoking history, known to
be EGFR and KRAS wild-type produced an ALK positivity
rate of 45%.9 Yi et al.10 only tested tumor specimens from
never smokers with adenocarcinoma, in whom 9.9% were
ALK FISH positive. In contrast, Paik et al.11 initially screened
all resected non-small cell lung cancer cases, in whom 4.2%
were ALK FISH positive. When Yi et al. screened an enriched
group, they inevitably increased the positive predictive value
of their test while reducing its negative predictive value,
something that should be borne in mind when considering
applying the same screening data to broader or narrower
populations than those within each original study.
Based on the high sensitivity of the applied ALK
immunostaining but its moderate specificity, both sets of
authors propose two-tier systems for evaluating ALK with an
initial immunohistochemical screening step followed by
FISH evaluation of 2, or both 1 and 2, IHC-positive
cases. Advantages of such a system include the large estab-
lished infrastructure that would be able to apply immuno-
staining methods to surgical pathology specimens and a
potential large reduction in the number of cases that would
require FISH testing. However, such a system would only
make sense if (a) the technology was reliable and offered
minimal false negatives, and (b) was cost-effective when
made truly reliable across multiple service providers. In
breast cancer, where a two-tier system for HER2 is currently
employed, preanalytic processing procedures, antibody stan-
dardization, and reproducibility of scoring between observers
have emerged as major issues.12 Preanalytical processing
steps in the handling of specimens are only cursorily ad-
dressed in the two studies reported in this issue of Journal of
Thoracic Oncology. With regard to the choice of antibodies,
each study used a different commercially available clone
(Table 1). Several studies, in addition to those in this edition
of the journal, have recently been published using different
anti-ALK antibodies, different comparators, and different scor-
ing systems conducted on differently enriched patient popu-
lations.7,8,13–15 In the study by Mino-Kenudson et al.,14 two
different anti-ALK antibodies were compared head-to-head,
showing significant differences in sensitivity by IHC. The TA
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best performing antibody (Cell Signaling clone D5F3), which
is currently not commercially available, showed far higher
sensitivity and specificity for finding FISH-positive cases
than the DAKO ALK1 antibody used by Yi et al. In addition,
the experimental antibody showed far higher reproducibility
between observers (Kappa score  0.94) than that demon-
strated within the Yi et al. study (Kappa score  0.55).10,14
The Novocastra antibody used by Paik et al. also showed a
high interobserver agreement (Kappa score  0.92); how-
ever, just as with the Cell Signaling antibody, should it
become commercially available, a high level of agreement
across multiple users and multiple different sites will be
required before any given IHC assay could be considered
reliable enough for widespread screening.11
When access to a specific drug (crizotinib) is likely to
be restricted to those with a defined molecular abnormality,
the avoidance of false negatives is imperative. Cut points for
submission of a specimen for FISH testing within any pro-
posed two-tier system would need careful consideration.
When Yi et al.10 raise the possibility of not FISH testing IHC
1 patients in their study of never-smoking adenocarcino-
mas, in which subgroup the ALK positivity rate by FISH was
still 5%, they are really suggesting that missing 10% of their
total ALK FISH-positive patients (1 of 10) would be accept-
able. While any kind of screening is certainly better than no
screening, given the overall poor prognosis of lung cancer
patients, we would suggest that such a strategy, as it stands,
would be less than ideal in the long term.
In addition to trying to develop simpler, quicker, and
cheaper screening tests to find the same population as the
break-apart FISH probe, other screening techniques, if opti-
mized further, could also offer something else. As only ALK
FISH-positive patients currently have access to crizotinib in
clinical trials, we do not know whether there are cases that
may be positive through other screening techniques, but
negative through ALK FISH testing, that may similarly ben-
efit from ALK inhibitor therapy. With the possibility of other
ALK screening tests becoming more widely available, in
conjunction with greater access to crizotinib, should it gain
accelerated approval within the United States, we may well
be able to expand the population benefiting from crizotinib
through careful exploration of some “atypical” FISH-nega-
tive cases in the future.
In conclusion, we believe that both studies in the
current issue of Journal of Thoracic Oncology are important
contributions to the development of a diagnostic/screening
paradigm for ALK in lung cancer. However, it seems clear
that IHC cannot fully replace FISH yet nor is a two-tier (IHC
then FISH) based screening system currently ready for prime
time. Considerable work is still required to assess and stan-
dardize the impact of sample preparation, antibody selection,
and signal quantification to generate reliable data for any
given IHC screening technique on its widespread reproduc-
ibility, sensitivity, and specificity. If we really want to aim for
a policy of no (true) ALK-positive patient being left behind,
we must set our sights high from the outset.
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